Patents by Inventor Arnold E. Postlethwaite
Arnold E. Postlethwaite has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200149108Abstract: This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or sublingually. This application also discloses methods for detecting variants. In addition the application addresses the use or avoidance of non steroidal anti inflammatory drugs in therapy.Type: ApplicationFiled: October 21, 2019Publication date: May 14, 2020Inventors: Arnold E. Postlethwaite, Weikuan Gu
-
Patent number: 10450610Abstract: This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or sublingually. This application also discloses methods for detecting variants. In addition the application addresses the use or avoidance of non steroidal anti inflammatory drugs in therapy.Type: GrantFiled: June 15, 2016Date of Patent: October 22, 2019Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Arnold E. Postlethwaite, Weikuan Gu
-
Publication number: 20170016068Abstract: This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or sublingually. This application also discloses methods for detecting variants. In addition the application addresses the use or avoidance of non steroidal anti inflammatory drugs in therapy.Type: ApplicationFiled: June 15, 2016Publication date: January 19, 2017Inventors: Arnold E. Postlethwaite, Weikuan Gu
-
Patent number: 9144595Abstract: One embodiment of a therapeutic composition comprises one or more APLs, e.g., APL A12, for treating diseases or disorders related to arthritis, including rheumatoid arthritis. Another embodiment includes a method of inducing a Th2-type cytokine secretion profile in a mammal, including administering a therapeutic amount of A12 analog peptide. Another embodiment includes a method for generating functional T regulatory cells, the method including administering a therapeutic amount of APL A12 to a RA patient.Type: GrantFiled: October 1, 2013Date of Patent: September 29, 2015Assignee: University of Tennessee Research FoundationInventors: Arnold E. Postlethwaite, Andrew Ho Kang, Linda K. Myers
-
Publication number: 20140286971Abstract: This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or sublingually. This application also discloses methods for detecting variants. In addition the application addresses the use or avoidance of non steroidal anti inflammatory drugs in therapy.Type: ApplicationFiled: April 3, 2014Publication date: September 25, 2014Applicant: THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Arnold E. Postlethwaite, Weikuan Gu
-
Publication number: 20140200201Abstract: Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds as shown in Tables 1 and 2. Also provided is a method for producing hydroxylated metabolites of cholecalciferol or ergocalciferol via the P450scc (CYP11A1) or CYP27B1 enzyme systems where the hydroxylase has an activity to hydroxylate position C20 of a secosteroid or its 5,7-dieneal precursor and the hydroxylated metabolites so produced. In addition, a method for inhibiting proliferation of either a normally or abnormally proliferating cell by contacting the cell with any of the compounds described herein. A related method is provided of treating a condition associated with the proliferating cell such as a cancer, a skin disorder, a defect in cell differentiation, cosmetic, prophylaxsis, or healthy cell maintenance.Type: ApplicationFiled: February 28, 2013Publication date: July 17, 2014Inventors: Andrzej T. Slominski, Robert C. Tuckey, Blazej Zbytek, Michal A. Zmijewski, Minh Ngoc Nguyen, Zorica Janjetovic, Jianjun Chen, Wei Li, Duane D. Miller, Jordan K. Zjawiony, Arnold E. Postlethwaite, Trevor W. Sweatman
-
Publication number: 20140113867Abstract: One embodiment of a therapeutic composition comprises one or more APLs, e.g., APL A12, for treating diseases or disorders related to arthritis, including rheumatoid arthritis. Another embodiment includes a method of inducing a Th2-type cytokine secretion profile in a mammal, including administering a therapeutic amount of A12 analog peptide. Another embodiment includes a method for generating functional T regulatory cells, the method including administering a therapeutic amount of APL A12 to a RA patient.Type: ApplicationFiled: October 1, 2013Publication date: April 24, 2014Inventors: Arnold E. Postlethwaite, Andrew Ho Kang, Linda K. Myers
-
Publication number: 20140107035Abstract: The present invention has demonstrated for the first time that orally administered type I collagen (CI) induced tolerance to CI in patients suffering from systemic sclerosis (SSc) and ameliorated clinical manifestations of the disease. Accordingly, the present invention provides methods of treating a fibrosing disease by oral administration of a tissue protein, for example, collagen, derived from the tissue undergoing fibrosis.Type: ApplicationFiled: December 13, 2013Publication date: April 17, 2014Applicant: The University of Tennessee Research FoundationInventors: Arnold E. Postlethwaite, Andrew H. Kang
-
Publication number: 20120258938Abstract: Provided herein are steroidal compounds that are androsta-5,7-dienes or pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof and cholecalciferol derivatives hydroxylated at one or more of C1, C17, C20, C23, C24, C25, and C26 which includes pharmaceutical, cosmeceutical or nutraceutical compositions of the steroidal compounds as shown in Tables 1A, 2A and 3. Also provided is a method for producing hydroxylated metabolites of cholecalciferol via CYP11A1, CYP24, CYP27A1, or CYP27B1 enzyme systems where the hydroxylase has an activity to hydroxylate position C1 or C20 or other position of the sidechain of a secosteroid or its 5,7-dieneal precursor and the hydroxylated metabolites so produced.Type: ApplicationFiled: April 30, 2012Publication date: October 11, 2012Inventors: Andrej Slominski, Robert C. Tuckey, Edith Tang, Elaine Tieu, Minh Nguyen, Zorica Janjetovic, Jianjun Chen, Wei Li, Yan Lu, Duane D. Miller, Jordan K. Zjawiony, Arnold E. Postlethwaite
-
Publication number: 20120135014Abstract: This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or sublingually. This application also discloses methods for detecting variants. In addition the application addresses the use or avoidance of non steroidal anti inflammatory drugs in therapy.Type: ApplicationFiled: April 20, 2009Publication date: May 31, 2012Applicant: The University of Tennessee Research FoundationInventors: Arnold E. Postlethwaite, Weikuan Gu
-
Publication number: 20110118228Abstract: Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds as shown in Tables 1 and 2. Also provided is a method for producing hydroxylated metabolites of cholecalciferol or ergocalciferol via the P450scc (CYP11A1) or CYP27B1 enzyme systems where the hydroxylase has an activity to hydroxylate position C20 of a secosteroid or its 5,7-dieneal precursor and the hydroxylated metabolites so produced. In addition, a method for inhibiting proliferation of either a normally or abnormally proliferating cell by contacting the cell with any of the compounds described herein. A related method is provided of treating a condition associated with the proliferating cell such as a cancer, a skin disorder, a defect in cell differentiation, cosmetic, prophylaxsis, or healthy cell maintenance.Type: ApplicationFiled: August 30, 2010Publication date: May 19, 2011Inventors: Andrzej Slominski, Wei Li, Blazej Zbytek, Robert C. Tuckey, Jordan K. Zjawiony, Minh Ngoc Nguyen, Zorica Janjetovic, Michal A. Zmijewski, Trevor W. Sweatman, Duane D. Miller, Jianjun Chen, Arnold E. Postlethwaite
-
Publication number: 20100179096Abstract: The present invention has demonstrated for the first time that orally administered type I collagen (CI) induced tolerance to CI in patients suffering from systemic sclerosis (SSc) and ameliorated clinical manifestations of the disease. Accordingly, the present invention provides methods of treating a fibrosing disease by oral administration of a tissue protein, for example, collagen, derived from the tissue undergoing fibrosis.Type: ApplicationFiled: March 29, 2010Publication date: July 15, 2010Applicant: The University of Tennessee Research FoundationInventors: Arnold E. Postlethwaite, Andrew H. Kang
-
Patent number: 7718765Abstract: The present invention has demonstrated for the first time that orally administered type I collagen (CI) induced tolerance to CI in patients suffering from systemic sclerosis (SSc) and ameliorated clinical manifestations of the disease. Accordingly, the present invention provides methods of treating a fibrosing disease by oral administration of a tissue protein, for example, collagen, derived from the tissue undergoing fibrosis.Type: GrantFiled: November 16, 2006Date of Patent: May 18, 2010Assignee: The University of Tennessee Research FoundationInventors: Arnold E. Postlethwaite, Andrew H. Kang
-
Patent number: 5962025Abstract: The present invention is directed to a method and pharmaceutical formulations for the treatment of systemic sclerosis in mammals, by oral administration of collagen, including type I collagen, or biologically active peptide fragments thereof.Type: GrantFiled: July 16, 1996Date of Patent: October 5, 1999Assignee: The University of Tennessee Research CorporationInventors: Laura Carbone, Andrew H. Kang, Kevin McKown, Arnold E. Postlethwaite, Jerome M. Seyer
-
Patent number: 5824647Abstract: Peptides corresponding to amino acid sequences in the C-terminal region of TGF-.beta. are provided. The peptides all contain at least a seven amino acid sequence substantially corresponding to the amino acid sequence of TGF-.beta.1 amino acids 368-374: VYYVGRK, as well as homologs and analogs thereof. The peptides have chemotactic activity towards fibroblasts, monocytes and neutrophils and induce fibroblast proliferation and collagen synthesis. The peptides may be used in compositions and methods for promoting wound healing.Type: GrantFiled: June 1, 1995Date of Patent: October 20, 1998Inventors: Arnold E. Postlethwaite, Jerome Seyer, Andrew Kang
-
Patent number: 5436228Abstract: Peptides corresponding to an no acid sequences in the C-terminal region of TGF-.beta. are provided. The peptides all contain at least a seven amino acid sequence substantially corresponding to the amino acid sequence of TGF-.beta.1 amino acids 368-374: VYYVGRK, as well as homologs and analogs thereof. The peptides have chemotactic activity towards fibroblasts, monocytes and neutrophils and induce fibroblast proliferation and collagen synthesis. The peptides may be used in compositions and methods for promoting wound healing.Type: GrantFiled: September 28, 1993Date of Patent: July 25, 1995Inventors: Arnold E. Postlethwaite, Jerome Seyer, Andrew Kang
-
Patent number: 5160483Abstract: A method and composition for promoting the healing of an open wound, such as a fresh surgical incision, a decubitus ulcer, or a diabetes ulcer. The method includes applying to the wound a therapeutically effective amount of a composition comprising a protein fragment of tumor necrosis factor .alpha.(TNF-.alpha.) including amino acids 31 through 68 SEQ ID NO.: 1. The composition may be applied topically or injected locally into a wound or ulcer site. A preferred composition includes a carrier medium selected from sterile water, sterile saline, and albumin. Topical formulations are administered as sprays, gels, ointments or salves.Type: GrantFiled: May 7, 1991Date of Patent: November 3, 1992Assignee: The University of Tennessee Research CorporationInventors: Arnold E. Postlethwaite, Jerome M. Seyer, Andrew H. Kang
-
Patent number: 5075288Abstract: A protein fragment for inducing sleep in mammals comprising a fragment of interleukin-1 .beta. from about amino acid 208 to about amino acid 240 and its physiologically active derivatives. The fragment comprises the amino acids sequence: ##STR1## The protein fragment may be derived by synthetic methods and a cysteine residue may be attached to the last threonine residue.Type: GrantFiled: September 5, 1990Date of Patent: December 24, 1991Assignee: The University of Tennessee Research CorporationInventors: James M. Krueger, Ferenc Obal, Jr., Arnold E. Postlethwaite, Jerome M. Seyer